Double vision

NuCana's $57M enough to get pivotal data for lead cancer program

Double vision

Sofinnova Ventures led NuCana BioMed Ltd.'s $57 million B round in the hopes its founders can once again bring a nucleoside-based cancer therapy to market.

NuCana's ProTide technology adds a phosphoramidate moiety to oncologic nucleosides to

Read the full 363 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE